Ulcer treatment works on two fronts at once: helping the sore itself heal, and removing whatever caused it. Skip the second and the ulcer tends to come back.
Reducing acid
The NIDDK's treatment guidance describes proton pump inhibitors and H2 blockers as the medications used to reduce stomach acid so the ulcer can heal, alongside antibiotics when H. pylori is involved. Lowering acid does not address an infection on its own, but it gives damaged tissue the conditions it needs to recover.
Clearing H. pylori — and what changed in 2024
If you read older articles about ulcer treatment, you will find them describing a combination built around an antibiotic called clarithromycin. That guidance has shifted, and it is the single most important thing to know about ulcer treatment today.
The 2024 ACG clinical guideline on H. pylori treatment recommends 14-day optimized bismuth quadruple therapy as the preferred first-line regimen for patients who have not been treated before and whose antibiotic susceptibility is unknown. That regimen combines a proton pump inhibitor, bismuth, and two antibiotics — tetracycline and metronidazole.
The reason for the change is antibiotic resistance. The Evidence-Based GI summary of the guideline explains that clarithromycin-based triple therapy should generally no longer be used as empirical first-line treatment in regions like North America, because clarithromycin resistance has become common enough to substantially reduce the odds of clearing the infection. Rifabutin-based triple therapy and regimens built around newer acid blockers such as vonoprazan sit alongside bismuth quadruple therapy as alternatives.
Confirming the treatment worked
Finishing the course is not the same as being cured, and this step gets skipped more than it should. The same ACG guideline calls for eradication to be confirmed after treatment using a breath test, stool antigen test, or biopsy-based test, with the timing set far enough after antibiotics and acid-suppressing therapy to avoid a false negative.
Feeling better is genuinely encouraging, but it is not proof the bacteria are gone. Persistent H. pylori keeps both the risk of ulcer recurrence and the longer-term risk of gastric cancer in play, which is what makes the follow-up test worth the inconvenience.
When NSAIDs are the cause
Where an ulcer is linked to anti-inflammatory use, the NIDDK describes the usual approach as some combination of stopping the NSAID, lowering the dose, switching to a different medicine, or adding a medication that protects the stomach, alongside ulcer-healing therapy. Every one of those options is a prescribing decision, and each involves a trade-off against whatever the NSAID was treating in the first place.
Surgery is uncommon in modern ulcer care. It is largely reserved for complications — perforation, bleeding that cannot be controlled another way, or an obstruction.